Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012IS127 Principal Investigator Greeno, Edward
Phase Phase III (Cancer Control)
Age Group Adult Scope National
Secondary Protocol No. 15982
Title A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Applicable Disease Sites Liver
Drugs Involved PLACEBO
Regorafenib
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Edward Greeno Phone:612-626-6418
Email:green048@tc.umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on